If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Many mothers have to return to work a short time after their babies have been born. In the U.S., about 70% of mothers with children younger than three years old work full-time, with 1/3 of the mothers returning to work within 3 months and 2/3 returning within 6 months. Working outside of the home and full-time work are significantly associated with lower rates of breastfeeding and breastfeeding for a shorter duration of time. According to the Centers for Disease Control and Prevention, support for breastfeeding in the workplace includes several types of employee benefits and services, including writing corporate policies to support breastfeeding women; teaching employees about breastfeeding; providing designated private space for breastfeeding or expressing milk; allowing flextime to support milk expression during work; giving mothers options for returning to work, such as remote work, part-time jobs, and extended maternity leave; providing on-site or near-site child care; providing high-quality breast pumps; and offering professional lactation consultants. Programs to promote and assist nursing mothers have been found to help maintain breastfeeding. In the United States the CDC reports on a study that "examined the effect of corporate lactation programs on breastfeeding behavior among employed women in California [which] included prenatal classes, perinatal counseling, and lactation management after the return to work".
In April 2007, Dein left Arsenal due to "irreconcilable differences" about the future of the club. Wenger described it as a "sad day for Arsenal," and sought assurances from the board over his future as well as reasons for Dein's departure. The instability at board level influenced club captain Henry's decision to leave Arsenal in June 2007, which led to uncertainty over Wenger's position. In September 2007, Wenger signed a new three-year extension, stating that he remained committed to "the club of my life." (In 2021, Wenger revealed that his signing of the contract extension was his side of a deal with the Arsenal board in the building of the new stadium, because he requested its construction.) Arsenal flourished in Henry's absence, with Emmanuel Adebayor, Mathieu Flamini and Fàbregas playing a more prominent role in the 2007–08 season. Defeat to Middlesbrough in December 2007 ended a run of 22 league matches unbeaten, but Arsenal soon built a five-point lead over Manchester United. A career-threatening injury to striker Eduardo against Birmingham City on 23 February 2008 acted as a turning point in Arsenal's season. Wenger, incensed at the aggressive tactics of opponents, called for a ban on tackler Martin Taylor in his post-match interview; he later retracted the comment. Arsenal's form subsequently suffered, and a run of three consecutive draws in March allowed Manchester United and Chelsea to overhaul them as they finished the season in third. Arsenal made a troubled start to Wenger's twelfth season.
In 1929, the country was renamed to Yugoslavia and the football association became Fudbalski savez Jugoslavije and ordered to move its headquarters from Zagreb to Belgrade. The national team participated at the 1930 FIFA World Cup, finishing in fourth place. In its first ever World Cup match in Montevideo's Parque Central, Yugoslavia managed a famous 2–1 win versus mighty Brazil, with the following starting eleven representing the country: Milovan Jakšić, Branislav Sekulić, Aleksandar Tirnanić, Milutin Ivković, Ivica Bek, Momčilo Đokić, Blagoje Marjanović, Milorad Arsenijević, Đorđe Vujadinović, Dragoslav Mihajlović, and Ljubiša Stefanović. The team was the youngest squad at the inaugural World Cup at an average age of just under 22 years old, and became quite popular among the Uruguayan public, who dubbed them "Los Ichachos". The national team consisted of players based in Serbian football clubs, while the Zagreb Subassociation forbid players from Croatian clubs, some of whom were regulars in the national team until then, to play in the World Cup due to the relocation of football association's headquarters from Zagreb to Belgrade.
Phrixotoxins are peptide toxins derived from the venom of the Chilean copper tarantula Phrixotrichus auratus, also named Paraphysa scrofa. Phrixotoxin-1 and -2 block A-type voltage-gated potassium channels; phrixotoxin-3 blocks voltage-gated sodium channels. Similar toxins are found in other species, for instance the Chilean rose tarantula.
PeptideAtlas is a proteomics data resource that gathers tandem mass spectrometry datasets from around the world, reprocesses them with the Trans-Proteomic Pipeline, and makes the combined result freely available to the community. Peptide Atlas is one of the founding members of the ProteomeXchange Consortium.
Sources: en.wikipedia.org
Canthaxanthin Chédiak–Higashi syndrome Chrysiasis Cross–McKusick–Breen syndrome (Cross syndrome, oculocerebral-hypopigmentation syndrome) Dermatopathia pigmentosa reticularis (dermatopathia pigmentosa reticularis hyperkeratotica et mutilans, dermatopathia pigmentosa reticularis hypohidotica et atrophica, dermatopathic pigmentosa reticularis) Dyschromatosis symmetrica hereditaria (reticulate acropigmentation of Dohi, symmetrical dyschromatosis of the extremities) Dyschromatosis universalis hereditaria Elejalde syndrome (Griscelli syndrome type 1) Eruptive hypomelanosis Familial progressive hyperpigmentation Galli–Galli disease Griscelli syndrome type 2 (partial albinism with immunodeficiency) Griscelli syndrome type 3 Hemochromatosis (bronze diabetes) Hemosiderin hyperpigmentation Hermansky–Pudlak syndrome Idiopathic guttate hypomelanosis (leukopathia symmetrica progressiva) Iron metallic discoloration Klein–Waardenburg syndrome Lead poisoning Leukoderma Melanoma-associated leukoderma Melasma (chloasma faciei, mask of pregnancy) Mukamel syndrome Necklace of Venus Nevus anemicus Nevus depigmentosus (nevus achromicus) Ocular albinism Oculocutaneous albinism Pallister–Killian syndrome Periorbital hyperpigmentation Photoleukomelanodermatitis of Kobori Phylloid hypomelanosis Piebaldism Pigmentatio reticularis faciei et colli Pityriasis alba Poikiloderma of Civatte Poikiloderma vasculare atrophicans Postinflammatory hyperpigmentation (postinflammatory hypermelanosis) Postinflammatory hypopigmentation Progressive macular hypomelanosis Quadrichrome vitiligo Reticular pigmented anomaly of the flexures (dark dot disease, Dowling–Degos' disease) Reticulate acropigmentation of Kitamura Revesz syndrome Riehl melanosis Scratch dermatitis (flagellate pigmentation from bleomycin) Segmental vitiligo Shah–Waardenburg syndrome Shiitake mushroom dermatitis (flagellate mushroom dermatitis, mushroom worker's disease, shiitake-induced toxicoderma) Tar melanosis (melanodermatitis toxica lichenoides) Tietz syndrome Titanium metallic discoloration Transient neonatal pustular melanosis (transient neonatal pustulosis, lentigines neonatorum) Trichrome vitiligo Vagabond's leukomelanoderma Vasospastic macule Vitiligo Vitiligo ponctué Vogt–Koyanagi–Harada syndrome Waardenburg syndrome Wende–Bauckus syndrome (Pegum syndrome) Woronoff's ring X-linked reticulate pigmentary disorder (familial cutaneous amyloidosis, Partington amyloidosis, Partington cutaneous amyloidosis, Partington syndrome type II, reticulate pigmentary disorder, X-linked reticulate pigmentary disorder with systemic manifestations) Yemenite deaf-blind hypopigmentation syndrome
The PDE5 inhibitors sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis) are prescription drugs which are taken by mouth. As of 2018, sildenafil is available in the UK without a prescription. Additionally, a cream combining alprostadil with the permeation enhancer DDAIP has been approved in Canada as a first line treatment for ED. Penile injections, on the other hand, can involve one of the following medications: papaverine, phentolamine, and prostaglandin E1, also known as alprostadil. In addition to injections, there is an alprostadil suppository that can be inserted into the urethra. Once inserted, an erection can begin within 10 minutes and last up to an hour. Medications to treat ED may cause a side effect called priapism.
== Determination of Beta Turns == Beta turns are another type of “short” or local secondary structure that is distinct from the more common helices, beta sheets or random coils. Beta turns are reasonably abundant (15%) and very important secondary structures in proteins. In particular, beta turns play a critical role in defining the topology of proteins. They also likely play a role in initiating early packing events during the protein folding process. In VADAR beta turns are identified under the BTURN header using standard Roman numeral notation (I = type I, II = type II, etc.). In VADAR, beta turns are identified using a combination of different pieces of information including hydrogen bond data, the location of previously identified secondary structures and the value of their local dihedral angles. In VADAR the classification and nomenclature used for beta turns follows the definitions proposed by Wilmot and Thornton.
== Cranial epidural space == In the skull, the periosteal layer of the dura mater adheres to the inner surface of the skull bones while the meningeal layer lays over the arachnoid mater. Between them is the epidural space. The two layers of the dura mater separate at several places, with the meningeal layer projecting deeper into the brain parenchyma forming fibrous septa that compartmentalize the brain tissue. At these sites, the epidural space is wide enough to house the epidural venous sinuses. There are four fibrous septa:
== Side effects == Rupatadine is a non-sedating antihistamine. However, as in other non sedating second-generation antihistamines, the most common side effects in controlled clinical studies were somnolence, headaches and fatigue.
Sources: en.wikipedia.org
By inhibiting this pathway, less collagen was produced and deposited in the heart, preventing the formation of cardiac fibrosis. Huang and Chen (2013) claim that oxymatrine may even be involved in inhibiting the expression of TGF-β1 receptors, which would further support that oxymatrine attenuates the signal transduction pathway involved in collagen production. They also reported that inhibition of the TGF-β1 receptor may also prevent ventricular remodeling.
He had to choose a college, and he chose to study at Magdalen College, Oxford, where his high school headmaster, Henry Girdlestone, had gone. He enrolled in the honour school of physiology, where he studied under the tutelage of Sir Charles Scott Sherrington. During the summer breaks he visited France, Belgium, Germany, Italy, Czechoslovakia and Austria. He became a demonstrator in the physiology department, and he applied for a fellowship in physiology at Merton College, but was passed over in favour of Gavin de Beer. He was awarded the degree of Bachelor of Arts in 1924. At Sherrington's instigation, he studied the cerebral cortex of cats. A paper was published in Brain in March 1925. His thesis on "The capillary circulation together with associated observations made in connexion with this investigation" was later examined by John Scott Haldane and John Gillies Priestley on 2 May 1925, and he was awarded a Bachelor of Science degree. Florey was elected to a John Lucas Walker Studentship at the University of Cambridge for the 1924–1925 academic year. This came with a stipend of £300 plus £200 for equipment. Before taking up this new position, he participated in the 1924 Oxford University Arctic Expedition as the medical officer. In July 1925, he won a fellowship from the Rockefeller Foundation to study in the United States.
The 227AcBe neutron sources can be applied in a neutron probe – a standard device for measuring the quantity of water present in soil, as well as moisture/density for quality control in highway construction. Such probes are also used in well logging applications, in neutron radiography, tomography and other radiochemical investigations. The medium half-life of 227Ac makes it a very convenient radioactive isotope in modeling the slow vertical mixing of oceanic waters. The associated processes cannot be studied with the required accuracy by direct measurements of current velocities (of the order 50 meters per year). However, evaluation of the concentration depth-profiles for different isotopes allows estimating the mixing rates. The physics behind this method is as follows: oceanic waters contain homogeneously dispersed 235U. Its decay product, 231Pa, gradually precipitates to the bottom, so that its concentration first increases with depth and then stays nearly constant. 231Pa decays to 227Ac; however, the concentration of the latter isotope does not follow the 231Pa depth profile, but instead increases toward the sea bottom. This occurs because of the mixing processes which raise some additional 227Ac from the sea bottom. Thus analysis of both 231Pa and 227Ac depth profiles allows researchers to model the mixing behavior.
=== Other sites and metastases === Metastasis of carcinoid can lead to carcinoid syndrome. This is due to the over-production of many substances, including serotonin, which are released into the systemic circulation, and which can lead to symptoms of cutaneous flushing, diarrhea, bronchoconstriction, and right-sided cardiac valve disease. It is estimated that less than 6% of carcinoid patients will develop carcinoid syndrome, and of these, 50% will have cardiac involvement.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.